The mental healthcare system is in desperate need of innovation.
By combining the growing potential of MDMA with digital therapeutics we aim to deliver safe, scalable psychotherapy to all those who need it — wherever and whenever they need it.
An atai Life Sciences company
EmpathBio is a biotech company dedicated to developing 3,4-Methylenedioxymethamphetamine derivatives in conjunction with digital therapeutics to deliver efficient, scalable treatments to patients on their own terms.
While MDMA-assisted psychotherapy holds great promise for the treatment of PTSD, refinement of MDMA's entactogenic pharmacology could provide for a greater therapeutic index. We want to ensure that entactogen-assisted psychotherapy is available to all struggling with PTSD.
- Glenn Short
, CEO, EmpathBio